Although patients who received tumor-infiltrating lymphocyte (TIL) therapy had favorable overall survival (OS), a significant number who were evaluated to receive lifileucel (Amtagvi) did not get ...

Researchers sought to determine an effective approach to predict postembolization fever in patients undergoing TACE.

OU Health Stephenson Cancer Center in Oklahoma City has started offering tumor-infiltrating lymphocyte (TIL) therapy as a ...

Make time for HUNKS The Show at Chisholm's Saloon (Oklahoma City, OK) 02/10/26 on the Oklahoma City Patch calendar ...

An increase in NLR values may be indicative of disease onset among patients with SSc and may help identify those at risk for poor outcomes.

Lilly joins the growing list of big pharma companies hoping to see success from their acquired in vivo CAR-T programmes.

Timely donor lymphocyte infusion (DLI) following the detection of impending molecular relapse may significantly improve ...

As of Wednesday, February 04, Zenas BioPharma, Inc.’s ZBIO share price has surged by 10.09%, which has investors questioning ...

A novel dual biologic regimen combining dazodalibep and belatacept is well tolerated and could enable more than half the ...

Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant ...

Patients with advanced melanoma experienced high response rates when treated with commercial Amtagvi in a real-world clinical ...

Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control RateSAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a ...